Pfizer (PFE) Set to Release Earnings on Wednesday

Pfizer (NYSE:PFE - Get Free Report) will post its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect Pfizer to post earnings of $0.57 per share for the quarter. Pfizer has set its FY24 guidance at $2.05-2.25 EPS.Investors interested in listening to the company's conference call can do so using this link.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm's revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.14 EPS. On average, analysts expect Pfizer to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pfizer Trading Down 0.2 %

Shares of PFE traded down $0.06 on Wednesday, reaching $26.26. 24,501,011 shares of the company's stock were exchanged, compared to its average volume of 41,887,898. The business has a 50 day moving average price of $27.05 and a two-hundred day moving average price of $28.50. The stock has a market capitalization of $148.70 billion, a P/E ratio of 72.94, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. Pfizer has a 12 month low of $25.23 and a 12 month high of $40.37. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.40%. Pfizer's dividend payout ratio (DPR) is presently 466.67%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on PFE shares. Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They issued a "buy" rating and a $36.00 price target for the company. Argus downgraded Pfizer from a "buy" rating to a "hold" rating in a report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Finally, TD Cowen cut Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Pfizer has an average rating of "Hold" and an average price target of $36.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.